Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a public biopharmaceutical company headquartered in San Diego, California, founded in 1992. Traded on the Nasdaq exchange under the ticker NBIX, the company had approximately 2,000 to 2,251 employees as of late 2025 and early 2026. For the twelve months ending March 31, 2026, Neurocrine Biosciences reported revenues of approximately $3.1 billion, with a market capitalization of around $16.4 billion as of June 2026.

Neurocrine Biosciences is a neuroscience-focused company dedicated to discovering, developing, and commercializing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Their portfolio includes FDA-approved products such as INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease, and CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia. The company also maintains a pipeline of drug candidates in various stages of clinical development targeting other high-unmet-need areas, including Parkinson's disease, Tourette syndrome, schizophrenia, and major depressive disorder.

Regarding patent litigation, Neurocrine Biosciences, Inc. shows a posture of actively asserting its intellectual property. The company has one tracked case as a plaintiff and zero as a defendant. This single case, filed in the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office, indicates engagement in challenging patent validity.

The company's sole tracked patent litigation case is Neurocrine Biosciences, Inc. v. Spruce Biosciences Inc, initiated on June 18, 2026, at the PTAB. This action suggests Neurocrine Biosciences is leveraging the PTAB process, a venue for challenging the patentability of claims in an issued patent, likely in relation to its core therapeutic areas or drug development pipeline.